ResMed Welcomes Urvashi Tyagi as New Chief Technology Officer
February 01 2022 - 9:00AM
ResMed Welcomes Urvashi Tyagi as New Chief Technology Officer
ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of
Urvashi Tyagi as chief technology officer (CTO), effective today.
As CTO, Tyagi will lead ResMed’s Digital Health Technology team,
driving the innovation and adoption of its world-leading
cloud-based digital health platforms, as well as investments in
emerging technologies like artificial intelligence and machine
learning.
Tyagi has over 25 years’ experience in IT and mechanical
engineering, user experience, finance, business development, and
executive leadership. Before joining ResMed, she was chief
technology officer and senior vice president for ADP. She was
previously global head of commercial data engineering for American
Express, and before that held senior roles at Amazon’s Audible
business, Microsoft, and IBM.
“Urvashi brings world-class technology and engineering know-how,
combined with senior leadership experience from other top fintech
and consumer tech companies, that will help ResMed accelerate
growth of our digital ecosystem, and achieve our goal of improving
the lives of 250 million people in 2025,” said ResMed CEO Mick
Farrell. “Urvashi has seen and developed best practices in
technology across multiple industries, and her strong leadership
and team development skills will help her infuse those learnings
and practices into the market-transforming work we do here at
ResMed.”
With Tyagi’s hire, previous CTO and current SaaS President Bobby
Ghoshal now transitions full-time into leading ResMed’s SaaS
business, which provides software solutions that enable thousands
of out-of-hospital care agencies to work more efficiently to
deliver personalized care.
“Bobby has done a tremendous job as ResMed’s first CTO, starting
in that role in 2018,” Farrell said. “I’d like to thank Bobby for
helping strengthen our Digital Health Technology team with
world-class talent and leadership, and I am excited that he can now
be laser focused on accelerating growth in our SaaS business,
building on the work he did as the COO for Brightree in 2016.
ResMed’s leadership in software as a service provides
market-leading solutions for healthcare providers, whole healthcare
systems, and most important, the tens of millions of patients,
residents, and seniors who rely on out-of-hospital care every
day.”
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more, visit
ResMed.com and follow @ResMed.
For mediaJayme Rubenstein+1
858.836.6798news@resmed.com |
|
For investorsAmy Wakeham+1
858.836.5000investorrelations@resmed.com |
|
|
|
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7f8c8bcd-cc85-4a41-8f68-a9e77c74f7f5
Resmed (LSE:0KW4)
Historical Stock Chart
From Dec 2024 to Jan 2025
Resmed (LSE:0KW4)
Historical Stock Chart
From Jan 2024 to Jan 2025